SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-008732
Filing Date
2022-05-10
Accepted
2022-05-10 08:01:50
Documents
58
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q avir-20220331.htm   iXBRL 10-Q 1951546
2 EX-31.1 avir-ex31_1.htm EX-31.1 17540
3 EX-31.2 avir-ex31_2.htm EX-31.2 17819
4 EX-32.1 avir-ex32_1.htm EX-32.1 12362
5 EX-32.2 avir-ex32_2.htm EX-32.2 11552
  Complete submission text file 0000950170-22-008732.txt   5120004

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT avir-20220331_def.xml EX-101.DEF 83631
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT avir-20220331_pre.xml EX-101.PRE 181736
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT avir-20220331_cal.xml EX-101.CAL 33551
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT avir-20220331_lab.xml EX-101.LAB 258530
10 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT avir-20220331.xsd EX-101.SCH 33054
52 EXTRACTED XBRL INSTANCE DOCUMENT avir-20220331_htm.xml XML 590759
Mailing Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110
Business Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110 857-204-8109
Atea Pharmaceuticals, Inc. (Filer) CIK: 0001593899 (see all company filings)

IRS No.: 460574869 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39661 | Film No.: 22907447
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences